Heterologous prime-boost immunization induces protection against dengue virus infection in cynomolgus macaques.
DNA vaccine
attenuated virus
dengue
prime-boost immunization
virus-like particle
Journal
Journal of virology
ISSN: 1098-5514
Titre abrégé: J Virol
Pays: United States
ID NLM: 0113724
Informations de publication
Date de publication:
30 Nov 2023
30 Nov 2023
Historique:
medline:
1
12
2023
pubmed:
17
10
2023
entrez:
17
10
2023
Statut:
ppublish
Résumé
Currently licensed dengue vaccines do not induce long-term protection in children without previous exposure to dengue viruses in nature. These vaccines are based on selected attenuated strains of the four dengue serotypes and employed in combination for two or three consecutive doses. In our search for a better dengue vaccine candidate, live attenuated strains were followed by non-infectious virus-like particles or the plasmids that generate these particles upon injection into the body. This heterologous prime-boost immunization induced elevated levels of virus-specific antibodies and helped to prevent dengue virus infection in a high proportion of vaccinated macaques. In macaques that remained susceptible to dengue virus, distinct mechanisms were found to account for the immunization failures, providing a better understanding of vaccine actions. Additional studies in humans in the future may help to establish whether this combination approach represents a more effective means of preventing dengue by vaccination.
Identifiants
pubmed: 37846984
doi: 10.1128/jvi.00963-23
pmc: PMC10688363
doi:
Substances chimiques
Antibodies, Viral
0
Dengue Vaccines
0
Vaccines, Virus-Like Particle
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0096323Subventions
Organisme : Wellcome Trust
ID : 203224/Z/16/Z
Pays : United Kingdom
Déclaration de conflit d'intérêts
N.S., P.K., N.C., and M.S.-L. were listed as inventors in patents and patent applications involving the mature virus-like particles of flaviviruses. Other authors declare that they do not have conflicts of interest.
Références
Clin Infect Dis. 2022 Aug 24;75(1):107-117
pubmed: 34606595
Elife. 2021 Jul 02;10:
pubmed: 34219653
Viruses. 2019 Mar 27;11(4):
pubmed: 30934772
Cell. 2015 Jul 30;162(3):493-504
pubmed: 26189681
Clin Infect Dis. 2018 Jan 6;66(2):178-184
pubmed: 29020332
Virol J. 2011 Jun 30;8:333
pubmed: 21714940
Lancet. 2014 Oct 11;384(9951):1358-65
pubmed: 25018116
J Virol. 2000 Apr;74(7):3011-9
pubmed: 10708415
J Virol. 2010 Aug;84(16):8353-8
pubmed: 20519400
Lancet Infect Dis. 2019 Jan;19(1):e31-e38
pubmed: 30195995
Proc Natl Acad Sci U S A. 2016 Jan 19;113(3):728-33
pubmed: 26729879
Virology. 2013 Apr 25;439(1):57-64
pubmed: 23453578
EMBO Mol Med. 2014 Mar;6(3):358-71
pubmed: 24421336
PLoS One. 2009;4(4):e4991
pubmed: 19337372
Virol J. 2014 Mar 12;11:48
pubmed: 24620925
Virus Res. 2023 Jan 2;323:199015
pubmed: 36455752
J Virol. 2017 Feb 14;91(5):
pubmed: 27974563
Nat Immunol. 2015 Jul;16(7):785
pubmed: 26086146
Asian Pac J Allergy Immunol. 2017 Mar;35(1):11-19
pubmed: 27001660
Vaccine. 2010 Jul 5;28(30):4827-36
pubmed: 20451642
J Virol. 2004 May;78(9):4761-75
pubmed: 15078958
N Engl J Med. 2015 Jan 8;372(2):113-23
pubmed: 25365753
Vaccine. 2000 May 26;18 Suppl 2:44-7
pubmed: 10821973
Int J Infect Dis. 2010 May;14(5):e377-83
pubmed: 19773190
Nat Commun. 2020 Jun 19;11(1):3112
pubmed: 32561757
Microbiol Spectr. 2023 Aug 17;11(4):e0091823
pubmed: 37409936
Sci Transl Med. 2020 Jan 29;12(528):
pubmed: 31996463
J Infect Dis. 2016 Oct 1;214(7):994-1000
pubmed: 27418050
Vaccine. 2013 Oct 17;31(44):5134-40
pubmed: 23973247
J Immunol. 2012 May 15;188(10):4971-9
pubmed: 22491255
Asian Pac J Allergy Immunol. 2021 Dec;39(4):287-295
pubmed: 31175718
Virology. 2010 Jan 20;396(2):280-8
pubmed: 19913867
PLoS One. 2014 Jun 02;9(6):e92643
pubmed: 24887426
EMBO J. 2012 Feb 1;31(3):767-79
pubmed: 22139356
J Clin Microbiol. 1999 Aug;37(8):2543-7
pubmed: 10405398
Proc Natl Acad Sci U S A. 2019 Jan 2;116(1):227-232
pubmed: 30518559
PLoS Negl Trop Dis. 2021 Mar 12;15(3):e0009258
pubmed: 33711074
Virology. 2009 Sep 15;392(1):103-13
pubmed: 19631955
Virol J. 2018 Apr 2;15(1):60
pubmed: 29609659
Lancet Infect Dis. 2017 Mar;17(3):e70-e78
pubmed: 28185869
J Virol. 2005 May;79(9):5516-28
pubmed: 15827166
Sci Transl Med. 2016 Mar 16;8(330):330ra36
pubmed: 27089205
Am J Trop Med Hyg. 1973 May;22(3):365-74
pubmed: 4196288
Am J Trop Med Hyg. 2011 Jun;84(6):978-87
pubmed: 21633037
J Infect Dis. 2017 Feb 1;215(3):351-358
pubmed: 27932620
PLoS One. 2009 Dec 15;4(12):e8325
pubmed: 20016834
J Clin Invest. 2021 Jul 1;131(13):
pubmed: 34003796
J Virol. 2007 Dec;81(23):12816-26
pubmed: 17881453
Nat Commun. 2021 Feb 17;12(1):1102
pubmed: 33597521
Science. 2017 Nov 17;358(6365):929-932
pubmed: 29097492
J Virol. 2013 Dec;87(23):12667-74
pubmed: 24049164
Virology. 2002 Jun 20;298(1):146-59
pubmed: 12093182
J Infect Dis. 2015 Sep 1;212(5):702-10
pubmed: 25801652
Vaccine. 2021 Aug 9;39(34):4759-4765
pubmed: 34253416
N Engl J Med. 2018 Jul 26;379(4):327-340
pubmed: 29897841
Nat Med. 2021 Aug;27(8):1395-1400
pubmed: 34168334
Vaccine. 2011 May 17;29(22):3863-72
pubmed: 21477675
mBio. 2015 Oct 13;6(5):e01461-15
pubmed: 26463165
J Virol. 2008 Nov;82(21):10776-91
pubmed: 18715923
Acta Trop. 2015 Feb;142:103-7
pubmed: 25460346
N Engl J Med. 2015 Sep 24;373(13):1195-206
pubmed: 26214039
J Virol Methods. 2001 Jun;95(1-2):19-32
pubmed: 11377710
J Virol Methods. 2014 Sep 1;205:116-23
pubmed: 24814967
Lancet. 2020 May 2;395(10234):1423-1433
pubmed: 32197105
J Gen Virol. 2015 Feb;96(Pt 2):288-293
pubmed: 25351518
J Virol. 2004 Mar;78(5):2367-81
pubmed: 14963133
Vaccine. 2015 Oct 13;33(42):5613-5622
pubmed: 26382602